Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-04-08 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司2021年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2021 from Harbin Pharmaceutical Group Co., Ltd. It details the independent directors' activities, attendance, opinions on management appointments, related party transactions, auditor reappointment, internal control evaluations, and overall governance observations. It is a narrative report on the independent directors' duties and oversight for the year, not a full annual report or audit report. It is not a brief announcement or a certification but a detailed report on governance and director activities. This fits best under Board/Management Information (MANG) as it relates to board members' roles and oversight rather than financial results or audit opinions alone.
2022-04-08 Chinese
哈药集团股份有限公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, financial statements, audit report mention, and comprehensive information about the company's operations and performance for the full fiscal year 2021. The length is substantial (15,000 characters), and it includes actual financial figures, management commentary, and audit opinions. This matches the definition of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, and it is not a quarterly or interim report. Therefore, the document is classified as an Annual Report (10-K). FY 2021
2022-04-08 Chinese
哈药集团股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including financial and non-financial internal control defects, their identification standards, and rectification status. The content is focused on internal control evaluation rather than full financial statements or audit opinions alone. It is not a full Annual Report (10-K) or an Audit Report (AR) but a specialized report on internal control evaluation. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document length is under 5,000 characters but contains substantive evaluation content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2021
2022-04-08 Chinese
哈药集团股份有限公司独立董事关于公司九届二十三次董事会相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors of 哈药集团股份有限公司 regarding their prior approval of certain board meeting agenda items, specifically about the company's 2022 expected related party transactions and the proposal to reappoint the auditing firm for 2021 audit work. It references compliance with company law, governance guidelines, and regulatory rules. The document is a formal declaration of the independent directors' opinions before the board meeting, not the actual audit report or financial statements. It is not a full annual report or audit report but a governance-related statement tied to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent directors' statements and approvals related to board decisions.
2022-04-08 Chinese
哈药集团股份有限公司2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2022 first extraordinary shareholders' meeting of 哈药集团股份有限公司. It details the meeting date, attendance, voting results on a director appointment, and legal witness statements confirming the validity of the meeting and voting process. There is no indication that this is a full report or financial statement. The content is a formal announcement of the voting results from a shareholders' meeting, specifically an extraordinary general meeting (EGM). This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation. Therefore, the classification is DVA with high confidence.
2022-03-22 Chinese
关于哈药集团股份有限公司2022年第一次临时股东大会之法律意见书
Regulatory Filings
2022-03-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.